Description: Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically-defined patient populations in the United States. Its lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion. The company was incorporated in 2019 and is based in New York, New York.
Home Page: elevationoncology.com
ELEV Technical Analysis
888 Seventh Avenue
New York,
NY
10106
United States
Phone:
716 371 1125
Officers
| Name | Title |
|---|---|
| Dr. Shawn M. Leland Pharm.D., R.Ph. | Founder, Pres, CEO & Director |
| Mr. Joseph J. Ferra Jr. | Chief Financial Officer |
| Ms. Valerie Malyvanh Jansen M.D., Ph.D. | Chief Medical Officer |
| Ms. Tammy Furlong CPA, P.M.P. | VP of Fin. & Accounting and Sec. |
| Dr. David Dornan Ph.D. | Chief Scientific Officer |
| Candice Masse | Sr. Director of Corp. Communications & Investor Relations |
| Mr. Robert C. Yang | VP of Legal Affairs |
| Mr. Brian Sullivan | VP of Corp. Devel. |
| Mr. Ryan Bloomer | Head of CMC |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0.1186 |
| Price-to-Book MRQ: | 0.3228 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2021-06-25 |
| Fiscal Year End: | December |
| Full Time Employees: | 48 |